NCT07362017

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Vanda Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Conditions

• Moderate-to-severe Chronic Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Ponesimod	Oral Tablet

Timeline

• Start date: 2026-01-01
• Primary completion: 2028-08-01
• Completion: 2028-12-01
• First posted: 2026-01-23
• Last updated: 2026-01-23

Regulatory

• FDA-regulated drug study